Intelligence Feed event · Capital · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share

    Direct answer

    ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 per share across 26.25 million shares, securing approximately $446.3 million in gross proceeds. The siRNA developer commences trading on Nasdaq under the ticker ADRX on September 25, 2026. The completed deal indicates sustained institutional risk appetite for late-stage clinical biopharma assets despite broader equity market softness and elevated cost of capital.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-nasdaq-ipo-at-17-per-share-d21cd0

    CAPITAL
    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
    ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 per share across 26.25 million shares, securing approximately $446.3 million in gross proceeds. The siRNA developer commences trading on Nasdaq under the ticker ADRX on September 25, 2026. The completed deal indicates sustained institutional risk appetite for late-stage clinical biopharma assets despite broader equity market softness and elevated cost of capital.
    ADRXXBI
    Impact
    71
    SEP 25
    SIG
    92%
    ADRXXBI
    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
    ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 per share across 26.25 million shares, securing approximately $446.3 million in gross proceeds. The siRNA developer commences trading on Nasdaq under the ticker ADRX on September 25, 2026. The completed deal indicates sustained institutional risk appetite for late-stage clinical biopharma assets despite broader equity market softness and elevated cost of capital.
    → Successful upsized primary ECM execution injects 446.3M USD into clinical RNA therapeutics, setting valuation benchmarks for late-stage biotech issuance.
    Impact
    ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 per share across 26.25 million shares, securing approximately $446.3 million in gross proceeds. The siRNA developer commences trading on Nasdaq under the ticker ADRX on September 25, 2026. The completed deal indicates sustained institutional risk appetite for late-stage clinical biopharma assets despite broader equity market softness and elevated cost of capital.
    Affected
    ADRXXBI
    Transmission
    Successful upsized primary ECM execution injects 446.3M USD into clinical RNA therapeutics, setting valuation benchmarks for late-stage biotech issuance.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXnew public market equity listing and liquidity intakeWatchintradayADARx priced 26.25 million shares at $17 each to raise $446.3 million gross proceeds.
    XBIbiotech primary issuance ECM market liquidity validationUp1-5dUpsized biotech IPO completions demonstrate institutional demand for clinical-stage pipelines.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed155.03 2026-09-25+1.02%-0.39%Pending
    ADRXWatch19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month